| Cancer |
| Metformin |
| Neoplasms |
| Prevention |
| Carcinoma |
| Risk |
| Incidence |
| Bisguanides |
| Type two Diabetes |
| Hypoglycaemic agents |
| Chemotherapy |
| Metformin monotherapy |
| Mortality |
| Cancer |
| Metformin |
| Neoplasms |
| Prevention |
| Carcinoma |
| Risk |
| Incidence |
| Bisguanides |
| Type two Diabetes |
| Hypoglycaemic agents |
| Chemotherapy |
| Metformin monotherapy |
| Mortality |